TaiRx

TaiRx Book Value per Share

The Book Value per Share of TaiRx (6580.TWO) as of Nov 16, 2026 is 3.94 TWD. In the previous year, Book Value per Share was 5.77 TWD — a change of -31.77% (lower).

Book Value per Share

3.94TWD

YoY

-31.77%

Last updated:

Book Value per Share of TaiRx is 2025 3.94 TWD. Book Value per Share of TaiRx was 2024 5.77 TWD. It decreases by -31.77% lower compared to the previous year.

The TaiRx Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Book Value per Share
Date
Book Value per Share
Jan 1, 2018
5.26 TWD
Jan 1, 2019
4.02 TWD
Jan 1, 2020
7.03 TWD
Jan 1, 2021
6.02 TWD
Jan 1, 2022
4.26 TWD
Jan 1, 2023
6.88 TWD
Jan 1, 2024
5.77 TWD
Jan 1, 2025
3.94 TWD
The TaiRx Book Value per Share history
YEARBook Value per ShareYoY
3.94TWD-31.77%
5.77TWD-16.15%
6.88TWD+61.53%
4.26TWD-29.17%
6.02TWD-14.47%
7.03TWD+74.78%
4.02TWD-23.52%
5.26TWD-25.98%
7.11TWD-13.50%
8.22TWD+15.35%
7.13TWD-10.12%
7.93TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

TaiRx Stock analysis

What does TaiRx do? TaiRx, Inc. generates revenue through the sale of its drug products, primarily targeting domestic medical institutions in Taipei. The company's commercialized drug Zelnite is distributed via distributors to medical facilities at all levels, while its pipeline includes CVM-1118 and Rexis, which are in clinical trials. The firm focuses on developing cancer treatment drugs and sepsis adjuvant therapy drugs, with TRX-NOC, TRX-920, TRX-711, and TRX-105 forming part of its product portfolio. Revenue streams derive from both current sales of Zelnite and future potential from clinical-stage products. TaiRx's primary customers are domestic medical institutions across Taipei, which purchase Zelnite through established distributor networks. The company's R&D efforts concentrate on advancing cancer therapeutics and sepsis treatments, with CVM-1118 and Rexis representing key pipeline assets currently undergoing clinical evaluation. The firm maintains a portfolio of drug candidates including TRX-NOC, TRX-920, TRX-711, and TRX-105, though these are not yet commercially available. The company's business model centers on developing novel drug products for cancer treatment and sepsis adjuvant therapy, with Zelnite being the only product currently sold to medical institutions. Clinical-stage products CVM-1118 and Rexis are in development, while TRX-NOC, TRX-920, TRX-711, and TRX-105 represent additional pipeline candidates. Revenue is derived from Zelnite sales through distributors, with future potential from the clinical-stage pipeline. TaiRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about TaiRx stock

Book Value per Share of TaiRx is 3.94 TWD in 2025.

Book Value per Share of TaiRx changed from 5.77 TWD to 3.94 TWD, representing a -31.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Book Value per Share TaiRx since 2006 – with annual values, charts, and detailed analysis.

Book value per share represents the net asset value of the company per outstanding share. Comparing it to the stock price helps assess whether a stock is undervalued.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — TaiRx

All Key Metrics — TaiRx